DaVita Upsizes Private Offering to $1 Billion

An update from DaVita ( (DVA) ) is now available.

On May 20, 2025, DaVita Inc. announced the upsize and pricing of its private offering of 6.750% senior notes due 2033, increasing the aggregate principal amount from $750 million to $1 billion. The proceeds from this offering are intended to repay outstanding credit facility borrowings and cover related expenses, with any remaining funds used for general corporate purposes. This strategic financial move is expected to close on May 23, 2025, and aims to strengthen DaVita’s financial position and operational flexibility.

The most recent analyst rating on (DVA) stock is a Sell with a $145.00 price target. To see the full list of analyst forecasts on DaVita stock, see the DVA Stock Forecast page.

Spark’s Take on DVA Stock

According to Spark, TipRanks’ AI Analyst, DVA is a Neutral.

DaVita’s overall score is driven by strong financial management and effective handling of operational challenges, such as a cybersecurity incident. The company’s high leverage and negative equity are significant risks, but these are partially offset by robust cash flow and strategic capital allocation. While technical indicators show some bearish sentiment, the valuation remains reasonable. Positive earnings call insights and maintained guidance further bolster the outlook.

To see Spark’s full report on DVA stock, click here.

More about DaVita

DaVita Inc. is a healthcare provider specializing in comprehensive kidney care, aiming to enhance the quality of life for patients worldwide. The company has been a leader in clinical quality and innovation for 25 years, offering services from slowing kidney disease progression to supporting transplantation and providing dialysis care in various settings.

Average Trading Volume: 926,813

Technical Sentiment Signal: Buy

Current Market Cap: $10.94B

See more insights into DVA stock on TipRanks’ Stock Analysis page.